iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

SEC Filings

Filing date	Form	Description	Filing Group	View
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020266.pdf 0000899243-20-020266.rtf 0000899243-20-020266.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020262.pdf 0000899243-20-020262.rtf 0000899243-20-020262.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020269.pdf 0000899243-20-020269.rtf 0000899243-20-020269.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020272.pdf 0000899243-20-020272.rtf 0000899243-20-020272.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020270.pdf 0000899243-20-020270.rtf 0000899243-20-020270.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020273.pdf 0000899243-20-020273.rtf 0000899243-20-020273.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0000899243-20-020274.pdf 0000899243-20-020274.rtf 0000899243-20-020274.xls
Jul 23, 2020	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	View HTML 0001104659-20-086052.pdf 0001104659-20-086052.rtf 0001104659-20-086052.xls
Jul 23, 2020	S-1MEF	Registration of up to an additional 20% of securities for any offering registered on an S-1	Registration Statements	View HTML 0001193125-20-198021.pdf 0001193125-20-198021.rtf 0001193125-20-198021.xls
Jul 23, 2020	EFFECT	EFFECT	Other	View HTML 9999999995-20-001898.pdf 9999999995-20-001898.rtf 9999999995-20-001898.xls

Data provided by Kaleidoscope.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our pipeline

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Explore our pipeline

About Us

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.

Meet our team

For investors

SEC Filings

Our pipeline

About Us